Stock KRBP KIROMIC BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Kiromic BioPharma, Inc.

Equities

KRBP

US4976342042

Market Closed - OTC Markets
Other stock markets
 16:51:07 03/07/2024 BST 		5-day change 1st Jan Change
2.22 USD -0.89% Intraday chart for Kiromic BioPharma, Inc. -1.33% +155.17%
06-20 Kiromic BioPharma, Inc. Provides Updates on Its Deltacel-01 Clinical Trial CI
06-07 Kiromic Biopharma, Inc. Issues 25% Senior Secured Convertible Promissory Note CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kiromic BioPharma, Inc. Provides Updates on Its Deltacel-01 Clinical Trial
Kiromic BioPharma, Inc. Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial
Kiromic BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Kiromic BioPharma, Inc. Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
Kiromic Biopharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
Kiromic BioPharma, Inc. Reports Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Deltacel-01 Clinical Trial
Kiromic BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Kiromic BioPharma, Inc. Announces Results from First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months
Kiromic Biopharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer
Kiromic Biopharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial
Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel? for the Treatment of Non-Small Cell Lung Cancer
Kiromic BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Kiromic Biopharma, Inc. Announces Deltacel?? Phase 1 Clinical Trial Enters Patient Recruitment Phase At Beverly Hills Cancer Center
Kiromic BioPharma, Inc. and Beverly Hills Cancer Center Enter Clinical Trial Agreement
Kiromic BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Kiromic Biopharma, Inc. Announces Board Appointments
Wall Street Set to Open Higher Amid Slowing Inflation; Consumer Sentiment Survey Eyed
Kiromic BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Top Premarket Gainers
Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KRBP Stock
  4. News Kiromic BioPharma, Inc.
  5. Other languages